Product Name :
BMVC
Description:
BMVC is a potent G-quadruplex (G4) stabilizer and a selective telomerase inhibitor with an IC50 of ~0.2 μM. BMVC inhibits Taq DNA polymerase with an IC50 of ~2.5 μM. BMVC increases the melting temperature of G4 structure of telomere and accelerates telomere length shortening. Anticancer activities.
CAS:
627810-06-4
Molecular Weight:
657.33
Formula:
C28H25I2N3
Chemical Name:
1-methyl-4-[(E)-2-{6-[(E)-2-(1-methylpyridin-1-ium-4-yl)ethenyl]-9H-carbazol-3-yl}ethenyl]pyridin-1-ium diiodide
Smiles :
[I-].[I-].C[N+]1C=CC(/C=C/C2=CC3C4=CC(/C=C/C5C=C[N+](C)=CC=5)=CC=C4NC=3C=C2)=CC=1
InChiKey:
FKOQWAUFKGFWLH-UHFFFAOYSA-M
InChi :
InChI=1S/C28H24N3.2HI/c1-30-15-11-21(12-16-30)3-5-23-7-9-27-25(19-23)26-20-24(8-10-28(26)29-27)6-4-22-13-17-31(2)18-14-22;;/h3-20H,1-2H3;2*1H/q+1;;/p-1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
BMVC is a potent G-quadruplex (G4) stabilizer and a selective telomerase inhibitor with an IC50 of ~0.2 μM. BMVC inhibits Taq DNA polymerase with an IC50 of ~2.5 μM. BMVC increases the melting temperature of G4 structure of telomere and accelerates telomere length shortening.{{BCI} MedChemExpress|{BCI} Phosphatase|{BCI} Protocol|{BCI} In Vitro|{BCI} custom synthesis|{BCI} Autophagy} Anticancer activities.{{Bebtelovimab} site|{Bebtelovimab} SARS-CoV|{Bebtelovimab} Biological Activity|{Bebtelovimab} Data Sheet|{Bebtelovimab} manufacturer|{Bebtelovimab} Autophagy} |Product information|CAS Number: 627810-06-4|Molecular Weight: 657.33|Formula: C28H25I2N3|Chemical Name: 1-methyl-4-[(E)-2-{6-[(E)-2-(1-methylpyridin-1-ium-4-yl)ethenyl]-9H-carbazol-3-yl}ethenyl]pyridin-1-ium diiodide|Smiles: [I-].[I-].C[N+]1C=CC(/C=C/C2=CC3C4=CC(/C=C/C5C=C[N+](C)=CC=5)=CC=C4NC=3C=C2)=CC=1|InChiKey: FKOQWAUFKGFWLH-UHFFFAOYSA-M|InChi: InChI=1S/C28H24N3.2HI/c1-30-15-11-21(12-16-30)3-5-23-7-9-27-25(19-23)26-20-24(8-10-28(26)29-27)6-4-22-13-17-31(2)18-14-22;;/h3-20H,1-2H3;2*1H/q+1;;/p-1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|BMVC (0.5 μM; 0-18 days; H1299 cells) treatment markedly increases the percentage of sub-G1-phase cells after 18 days. BMVC (0.5 μM; 0-18 days; H1299 cells) long-term treatment leads to ceasing of cell growth and eventually cell death through apoptosis.PMID:33256538 The long-term BMVC treatment induces senescence program in H1299 cells. In BMVC-treated cancer cells, hallmarks of senescence, including morphologic changes, detection of senescence-associated β-galactosidase activity, and decreasesd bromodeoxyuridine incorporation, are detected. The BMVC-induced senescence phenotype is accompanied by progressive telomere shortening and detection of the DNA damage foci, indicating that BMVC caused telomere uncapping after long-term treatments. BMVC also suppresses the tumor-related properties of cancer cells, including cell migration, colony-forming ability, and anchorage-independent growth.|In Vivo:|BMVC (1 mg/kg; intraperitoneal injection; every 3 day; BALB/cAnN.Cg-Foxn1nu/CrlNarl mice) treatment delays tumorigenic potential of cancer cells in vivo.|Products are for research use only. Not for human use.|